Helsinn Healthcare S.A.: Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor

Helsinn Group announces oral presentation of data at AACR-NCI-EORTC relating to a potent and highly selective investigational RET inhibitor Lugano, Switzerland, 7 October 2021 - Helsinn

Related Keywords

China ,Lugano ,Ticino ,Switzerland ,Japan ,Swiss ,Isao Miyazaki ,Kostenloser Wertpapierhandel ,Paola Bonvicini ,Johns Hopkins ,Sergio Cantoreggi ,Ireland Helsinn Birex Pharmaceuticals Ltd ,Linkedin ,Us Helsinn Therapeutics Inc ,Taiho Pharmaceutical Co Ltd ,Twitter ,Virtual International Conference On Molecular ,China Helsinn Pharmaceuticals Beijing Co Ltd ,Group Head Of Communication ,Swiss Biopharmaceutical Group ,Helsinn Group Media Contact ,Group Head ,Helsinn Group ,Otsuka Holdings Co Ltd ,International Conference ,Molecular Targets ,Cancer Therapeutics ,New Drugs ,Group Chief Scientific Officer ,Non Small Cell Lung Cancer ,Cancer Biol Ther ,Cell Rep ,Nat Med ,Nat Rev Clin Oncol ,Onco Targets Ther ,Helsinn Therapeutics ,Helsinn Pharmaceuticals ,Helsinn Birex Pharmaceuticals Ltd ,Taiho Pharmaceutical ,Group Media Contact ,Helsinn ,Healthcare ,Group ,Nnounces ,Mural ,Presentation ,Data ,Racr ,Hortc ,Elating ,Kpotent ,Ighly ,Elective ,Investigational ,Inhibitor ,